Verici Dx plc (VRCDF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Verici Dx plc (VRCDF) trades at $0.00 with AI Score 61/100 (Grade B+). Verici Dx plc is an immuno-diagnostics development company focused on the kidney transplantation market. Market cap: $5.01M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for VRCDF: VRCDF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VRCDF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
VRCDF: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Verici Dx plc (VRCDF) Healthcare & Pipeline Overview
Verici Dx plc is a UK-based immuno-diagnostics company specializing in the kidney transplantation market, developing prognostic and diagnostic tests. Its in-development pipeline includes Clarava for pre-transplant risk, Tuteva for acute cellular rejection, and Protega, a liquid biopsy for long-term graft failure, aiming to enhance patient care.
What Is the Investment Thesis for VRCDF?
Verici Dx plc presents an investment profile centered on its specialized focus within the high-need kidney transplantation diagnostics market. The company's value drivers are primarily its in-development pipeline, which includes Clarava for pre-transplant prognosis, Tuteva for post-transplant acute cellular rejection, and Protega for long-term graft failure prediction. These tests address critical junctures in kidney transplant patient management, offering potential for improved outcomes and reduced healthcare costs. Key growth catalysts include successful progression through clinical development, achievement of regulatory approvals (e.g., FDA, CE Mark), and subsequent commercialization of its diagnostic tests. The company's gross margin of 105.8% suggests a unique revenue structure or accounting for a development-stage entity, while its significant negative profit margin of -468.3% underscores its early-stage, R&D-intensive nature. Risks include the inherent challenges of clinical development, regulatory hurdles, potential for limited market adoption, and intense competition in the diagnostics space. As an OTC-listed company with a $5.01M market cap and a beta of 1.30, it exhibits characteristics of a highly speculative, early-stage venture with elevated volatility.
Based on FMP financials and quantitative analysis
VRCDF Key Highlights
- The company maintains a highly specialized focus on immuno-diagnostics for the kidney transplantation market.
- Verici Dx plc reported a gross margin of 105.8%, indicating a unique revenue or cost structure for a development-stage company.
- The company recorded a significant negative profit margin of -468.3%, reflecting its current R&D-intensive phase and lack of commercialized products.
- With a beta of 1.30, the stock exhibits higher volatility compared to the broader market, consistent with an early-stage healthcare company.
- The company operates with a lean structure, employing 19 individuals, focusing resources on its core diagnostic development.
Who Are VRCDF's Competitors?
VRCDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| STIM Neuronetics, Inc. | $1.56 | +10.64% | $108.56M | 61 |
| GTH Genetron Holdings Limited | $4.03 | +0.12% | $127.29M | 61 |
| BNR Burning Rock Biotech Limited | $10.33 | +6.83% | $10.92M | 62 |
| STRR Star Equity Holdings, Inc. | $11.19 | +1.82% | $41.36M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VRCDF's Key Strengths?
- Highly specialized focus on immuno-diagnostics for kidney transplantation, addressing a critical medical need.
- Pipeline of three distinct in-development tests (Clarava, Tuteva, Protega) covering different stages of transplant care.
- Development of Protega as a liquid biopsy aligns with modern trends towards non-invasive diagnostics.
- Incorporated in the UK, potentially leveraging European research and healthcare networks.
What Are VRCDF's Weaknesses?
- Early-stage company with a significant negative profit margin (-468.3%), indicating unprofitability and reliance on R&D funding.
- Small employee base (19) may limit the pace of multiple product developments and commercialization efforts.
- Reliance on the successful clinical development and regulatory approval of its pipeline products.
- Listing on the OTC market may limit institutional investor access and liquidity.
What Could Drive VRCDF Stock Higher?
- Announcement of positive clinical trial results for Clarava, Tuteva, or Protega, validating their efficacy and safety.
- Achievement of key regulatory milestones, such as FDA clearance or CE Mark approval, for any of its diagnostic tests.
- Successful commercial launch of its first diagnostic product, signaling a transition from development to revenue generation.
- Continued progress in the research and development of its diagnostic pipeline, advancing tests towards commercial readiness.
What Are the Key Risks for VRCDF?
- Financial-distress signal — its Altman Z-Score of -10.02 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant negative profit margin of -468.3% indicates substantial operational losses and reliance on external funding for continuity.
- Clinical trial failures or unexpected delays in the development of Clarava, Tuteva, or Protega could severely impact future prospects.
- Regulatory hurdles and prolonged approval processes could delay market entry and increase development costs.
- Limited market adoption or challenges in securing favorable reimbursement for its diagnostic tests upon commercialization.
- Intense competition from established diagnostic companies with greater financial and market resources.
What Are the Growth Opportunities for VRCDF?
- **Clarava Market Penetration:** The successful development and commercialization of Clarava, a pre-transplant prognosis test for early acute rejection risk, represents a significant growth opportunity. By providing critical insights before transplantation, Clarava could enable more informed clinical decisions, potentially leading to better patient-donor matching and optimized initial immunosuppression. The global kidney transplant market continues to grow, with a persistent need for tools that can improve long-term graft survival and reduce early complications. Capturing even a fraction of this market, estimated to be worth billions globally for transplant diagnostics, would drive substantial revenue upon regulatory approval and market adoption, likely within the next 3-5 years.
- **Tuteva Commercialization and Adoption:** Tuteva, a post-transplant test focusing on acute cellular rejection, offers another key growth pathway. Acute cellular rejection remains a major challenge after kidney transplantation, requiring vigilant monitoring and timely intervention. A highly accurate and reliable diagnostic tool like Tuteva could become a standard of care, leading to widespread adoption by transplant centers. The market for post-transplant monitoring is substantial, driven by the ongoing need to prevent and manage rejection episodes throughout a patient's life. Successful clinical validation and subsequent market entry could establish Tuteva as a leading solution within the next 2-4 years.
- **Protega Liquid Biopsy Development and Expansion:** The development and eventual launch of Protega, a liquid biopsy test predicting the risk of fibrosis and long-term graft failure, taps into the rapidly expanding field of non-invasive diagnostics. Liquid biopsies offer significant advantages over traditional tissue biopsies, including reduced patient burden and the ability for more frequent monitoring. As the industry shifts towards less invasive and more predictive diagnostics, Protega could capture a substantial share of the long-term graft monitoring market. This innovative approach could provide a competitive edge, with market potential growing significantly over the next 5-7 years as liquid biopsy technologies mature and gain broader acceptance.
- **Geographic Market Expansion:** Currently based in the United Kingdom, Verici Dx plc has a significant opportunity to expand its market reach beyond its home country. Key markets such as the United States and major European Union countries represent substantial pools of kidney transplant patients and advanced healthcare systems. Establishing regulatory approvals and commercial partnerships in these regions would dramatically increase the addressable market for its diagnostic tests. This expansion would require strategic investments in sales, marketing, and regulatory affairs, potentially unfolding over a 5-10 year horizon as products gain traction in initial markets.
- **Pipeline Diversification and Platform Leverage:** Beyond its current three core tests, Verici Dx plc has the potential to leverage its immuno-diagnostics platform and expertise to develop tests for other organ transplants (e.g., heart, liver, lung) or related immunological conditions. This diversification would broaden its product portfolio and reduce reliance on the kidney transplantation market alone. The underlying scientific principles and technological infrastructure developed for Clarava, Tuteva, and Protega could be adapted to address similar diagnostic needs in other transplant settings, opening up new multi-billion dollar markets over the long term, potentially within 7-10 years.
What Opportunities Does VRCDF Have?
- Growing global demand for kidney transplants and improved diagnostic tools to prevent rejection and graft failure.
- Expansion into major international markets such as the US and EU upon successful product commercialization.
- Leveraging its immuno-diagnostics platform to develop tests for other organ transplants or related immunological conditions.
- Increasing adoption of non-invasive liquid biopsy technologies in diagnostics.
What Threats Does VRCDF Face?
- High regulatory hurdles and potential for delays or failures in obtaining necessary approvals for diagnostic tests.
- Intense competition from larger, more established diagnostic companies with greater resources.
- Clinical trial failures or inconclusive results for any of its in-development tests.
- Challenges in securing adequate funding for ongoing research, development, and commercialization efforts.
- Potential for limited market adoption or unfavorable reimbursement policies upon product launch.
What Are VRCDF's Competitive Advantages?
- Specialized focus on the niche yet critical kidney transplantation immuno-diagnostics market.
- Development of proprietary diagnostic tests (Clarava, Tuteva, Protega) addressing specific unmet clinical needs.
- Potential for intellectual property protection through patents covering its diagnostic methodologies and biomarkers.
- Early-mover advantage in developing specific prognostic and diagnostic solutions for various stages of kidney transplantation.
What Does VRCDF Do?
Verici Dx plc, incorporated in 2020 and headquartered in Penarth, United Kingdom, operates as an immuno-diagnostics development company singularly focused on the critical kidney transplantation market. The company's strategic objective is to address significant unmet needs in patient management by developing advanced prognostic and diagnostic tests tailored for kidney transplant recipients. Its product pipeline is designed to cover key stages of the transplant journey, from pre-transplant risk assessment to post-transplant monitoring and long-term graft health prediction. Among its in-development tests is Clarava, a pre-transplant prognosis test engineered to assess the risk of early acute rejection, providing clinicians with crucial information to optimize patient matching and initial immunosuppression strategies. Following transplantation, the company is developing Tuteva, a specialized test designed to detect and monitor acute cellular rejection, a common and serious complication that can compromise graft survival. Furthermore, Verici Dx plc is advancing Protega, an innovative liquid biopsy solution. Protega aims to predict the risk of fibrosis and long-term graft failure, offering a non-invasive method to monitor the chronic health of the transplanted kidney. With a dedicated team of 19 employees, Verici Dx plc positions itself within a niche but high-impact segment of the healthcare sector, striving to enhance the longevity and success rates of kidney transplants through precision diagnostics. The company's foundational premise revolves around leveraging immuno-diagnostics to provide actionable insights that can lead to more personalized and effective patient management protocols, ultimately improving the quality of life and survival rates for kidney transplant patients globally.
What Products and Services Does VRCDF Offer?
- Develops immuno-diagnostic tests specifically for the kidney transplantation market.
- Focuses on improving patient outcomes for individuals undergoing kidney transplants.
- Offers Clarava, a pre-transplant test for predicting the risk of early acute rejection.
- Develops Tuteva, a post-transplant test designed to detect acute cellular rejection.
- Is advancing Protega, a liquid biopsy test to predict the risk of fibrosis and long-term graft failure.
- Aims to provide prognostic and diagnostic insights to clinicians throughout the transplant journey.
- Operates as a development-stage company, incorporated in 2020 and based in Penarth, United Kingdom.
How Does VRCDF Make Money?
- Primarily focused on the research and development of novel diagnostic tests for kidney transplant patients.
- Anticipates generating revenue through the sale of its proprietary diagnostic tests (Clarava, Tuteva, Protega) upon successful commercialization.
- Targets transplant centers, nephrologists, and healthcare systems as primary customers for its diagnostic solutions.
- May pursue licensing agreements or partnerships to facilitate broader market access and distribution of its tests.
What Industry Does VRCDF Operate In?
Verici Dx plc operates within the Medical - Diagnostics & Research industry, a segment of the broader Healthcare sector characterized by continuous innovation and a strong emphasis on scientific advancement. The company's specific niche is immuno-diagnostics for kidney transplantation, a critical area where accurate and timely diagnostic tools can significantly impact patient outcomes and healthcare costs. The market for organ transplantation diagnostics is driven by the increasing number of transplants performed globally and the persistent challenge of graft rejection and failure. Trends indicate a growing demand for non-invasive, highly sensitive, and specific diagnostic tests, such as liquid biopsies, which Protega aims to address. The competitive landscape includes established diagnostic companies with broader portfolios, as well as smaller, specialized biotech firms. Verici Dx plc positions itself by focusing on specific, in-development tests designed to fill identified gaps in current kidney transplant patient management protocols, aiming to differentiate through precision and prognostic capabilities.
Who Are VRCDF's Key Customers?
- Kidney transplant centers and their associated medical teams.
- Nephrologists and transplant surgeons seeking advanced diagnostic tools.
- Hospitals and healthcare systems managing kidney transplant patient populations.
- Indirectly, kidney transplant patients who benefit from improved diagnostic accuracy and personalized care.
Key Financial Metrics
Return on assets is -78.6%, showing how much profit it generates from its asset base. A current ratio of 3.94 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -82.3%, the inverse of the P/E and a quick read on earnings relative to price.
Verici Dx plc (VRCDF) Valuation Context
Valued at $5.01M, VRCDF is classified as a micro-cap stock. Relative to its peer group, VRCDF's quantitative score of 61/100 is roughly in line with the peer average of 66/100.
Company Profile
Verici Dx plc operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Penarth, GB. The company is led by CEO Sara jane Barrington. VRCDF has traded publicly since 2022.
F-Score 3/9Financial Health
Verici Dx plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.02 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Verici Dx plc revenue of about $4.9M for fiscal 2026, with EPS near $-0.00.
VRCDF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Verici Dx's focus on kidney transplant diagnostics addresses a critical unmet need, potentially leading to strong adoption if clinical data continues to impress.
- Positive community sentiment suggests growing investor confidence in Verici Dx's long-term strategy and market potential.
- Recent insider activity, if showing increased buying, could signal strong internal belief in the company's future prospects.
- The company's targeted approach to a specific area of diagnostics could allow for focused development and faster regulatory pathways.
Bear Case
- Market perception of small-cap biotech companies can be volatile, making Verici Dx susceptible to significant price swings based on broader market trends.
- Negative community sentiment, even if localized, could indicate concerns about the company's progress or competitive landscape.
- If insider activity reveals selling, it might suggest a lack of confidence in the short-term outlook or a need for liquidity.
- The success of Verici Dx hinges on successful clinical trials and regulatory approvals, introducing significant risk and uncertainty.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VRCDF Latest News
-
CORRECTING and REPLACING Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
businesswire.com · May 19, 2026
-
Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
businesswire.com · May 19, 2026
VRCDF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VRCDF.
Price Targets
Wall Street price target analysis for VRCDF.
VRCDF MoonshotScore
What does this score mean?
The MoonshotScore rates VRCDF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
CORRECTING and REPLACING Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
Leadership: Sara jane Barrington
Chief Executive Officer
The specific career history, educational background, and previous roles of Sara jane Barrington are not provided in the source data. She is identified as managing the company's 19 employees, indicating a leadership role central to the company's operations and strategic direction.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Sara jane Barrington's leadership are not detailed in the provided information. Her role as the leader of Verici Dx plc, an immuno-diagnostics development company, implies oversight of the company's focus on the kidney transplantation market and the development of its key diagnostic tests.
VRCDF OTC Market Information
Verici Dx plc trades on the 'OTC Other' tier of the OTC market. This tier is typically reserved for companies that do not meet the financial or disclosure requirements of higher OTC tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies on the 'OTC Other' tier often have limited public disclosure, which can make it challenging for investors to access comprehensive financial and operational information. This tier is generally associated with micro-cap or penny stocks and is considered the most speculative segment of the OTC market, often with fewer regulatory oversight requirements compared to national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure and transparency, making it difficult for investors to obtain comprehensive financial and operational information.
- Significantly lower liquidity compared to major exchanges, potentially leading to wide bid-ask spreads and difficulty in executing trades.
- Increased susceptibility to price manipulation and volatility due to less stringent regulatory oversight and smaller market capitalization.
- Difficulty in attracting institutional investors, which can further limit trading volume and capital access.
- Potential for delisting or further fragmentation of trading if disclosure standards are not met or maintained.
- Verify the company's official registration and legal standing in the United Kingdom.
- Seek out any available financial statements, even if not regularly filed, to assess financial health and burn rate.
- Research the progress of its diagnostic pipeline through company press releases or scientific publications.
- Investigate any news or updates regarding regulatory approvals for its products in target markets.
- Understand the competitive landscape within kidney transplant diagnostics and Verici Dx plc's positioning.
- Assess the management team's experience and track record, if additional information becomes available.
- Examine the company's capital structure and any recent fundraising activities.
- Clear and specific business description focused on immuno-diagnostics for kidney transplantation.
- Identified pipeline of three distinct in-development diagnostic tests (Clarava, Tuteva, Protega).
- Incorporated in 2020 and based in Penarth, United Kingdom, indicating a formal corporate structure.
- Presence of a named CEO, Sara jane Barrington, managing the company's operations.
- Focus on a high-need medical area with potential for significant clinical impact.
Verici Dx plc Healthcare Stock: Key Questions Answered
What does Verici Dx plc do?
Verici Dx plc is an immuno-diagnostics development company established in 2020 and based in Penarth, United Kingdom. The company is dedicated to creating advanced prognostic and diagnostic tests specifically for patients undergoing kidney transplantation. Its pipeline includes Clarava, a pre-transplant test to assess the risk of early acute rejection; Tuteva, a post-transplant test for monitoring acute cellular rejection; and Protega, an innovative liquid biopsy designed to predict the risk of fibrosis and long-term graft failure. These tests aim to provide clinicians with critical insights to improve patient management, enhance graft survival, and ultimately improve the quality of life for kidney transplant recipients.
What is the current status of Verici Dx plc's diagnostic pipeline?
Verici Dx plc's diagnostic pipeline consists of three key in-development tests. Clarava is a pre-transplant prognosis test focused on the risk of early acute rejection. Tuteva is a post-transplant test designed to detect acute cellular rejection. Protega is an innovative liquid biopsy aiming to predict the risk of fibrosis and long-term graft failure. All three products are currently in development, indicating the company is in the research and clinical validation phases rather than commercialization. The successful progression through these development stages, including clinical trials and regulatory approvals, will be critical milestones for the company's future.
What are the primary financial characteristics of Verici Dx plc?
Verici Dx plc exhibits financial characteristics typical of an early-stage development company. It currently has a market capitalization of $5.01M, reflecting its nascent stage. The company reported a gross margin of 105.8%, which is an unusual metric that may indicate a specific accounting treatment for a development-stage entity or revenue from grants/services rather than product sales. Critically, it has a significant negative profit margin of -468.3%, underscoring its current unprofitability and substantial investment in research and development. With a beta of 1.30, the stock demonstrates higher volatility compared to the broader market, consistent with its early-stage and speculative nature.
What are the implications of Verici Dx plc's listing on the OTC market?
Verici Dx plc's listing on the OTC Other tier of the OTC market carries several implications for investors. This tier typically signifies less stringent disclosure requirements compared to major exchanges or even higher OTC tiers, potentially leading to limited publicly available financial and operational information. Trading on the OTC market often results in lower liquidity, characterized by wider bid-ask spreads and lower trading volumes, which can make it challenging to buy or sell shares efficiently. Furthermore, OTC stocks may be subject to higher volatility and are generally considered more speculative, requiring investors to conduct extensive due diligence due to reduced regulatory oversight.
What are the key factors to evaluate for VRCDF?
Verici Dx plc (VRCDF) holds an AI score of 61/100 (moderate). Not financial advice.
How frequently does VRCDF data refresh on this page?
VRCDF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VRCDF's recent stock price performance?
Verici Dx plc (VRCDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Highly specialized focus on immuno-diagnostics for kidney transplantation, addressing a critical medical need. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VRCDF overvalued or undervalued right now?
Valuing Verici Dx plc (VRCDF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information on CEO background/track record, specific market sizes for growth opportunities, and a detailed competitive landscape beyond general industry context is limited in the provided source data.
- The interpretation of the 105.8% gross margin is based solely on the provided numerical fact, without additional context or explanation from the source data.